Berlin, September 27, 2017 – Medios AG, one of the leading competence partners and solution providers for specialty pharmaceuticals in Germany, has benefited from a strong demand for personalized medicine in the first half of 2017 and confirms the forecast for the full year, which was raised in August 2017. Accordingly, the Management Board expects sales of EUR 230 million and earnings before taxes (EBT) of around EUR 7.0 million to EUR 7.5 million.
According to the consolidated half-year financial report (IFRS) published today, sales generated from January to June increased by 59 percent to EUR 117.0 million compared to the prior year period (prior year EUR 73.6 million, pro-forma IFRS). The EBT increased by 40 percent to EUR 3.9 million (prior year EUR 2.8 million, pro-forma IFRS) while the consolidated net profit rose by 61 percent to EUR 2.6 million (prior year EUR 1.6 million, pro-forma IFRS). Thereby, the preliminary figures (IFRS), which had already been published in August, are being confirmed. The equity rate was 62.6 percent on the reporting date of June 30, 2017.
In the specialty pharma wholesale segment, sales rose by 70 percent to EUR 97.6 million over the prior year’s period (prior year EUR 57.5 million, IFRS*). The EBT increased by 56 percent to EUR 3.2 million (prior year EUR 2.1 million, IFRS*). In the patient-specific preparations segment, sales rose by 26 percent to EUR 26.1 million (prior year EUR 20.7 million, IFRS*). The EBT remained stable at EUR 0.9 million (prior year EUR 0.9 million, IFRS*).
Manfred Schneider, CEO of Medios AG: “Steadily strong demand for personalized medicine and new approvals for high-priced innovative therapies are gradually bringing us closer to our goal of becoming the leading supplier of specialty pharma solutions in Germany. In the future, we intend to increase the number of partners and products significantly. Moreover, we will also build a new manufacturing facility as announced, thus expanding the capacity for manufacturing patient-specific infusions and preparations.”
For Medios, the first half of 2017 was characterized by a lot of decisions concerning the growth strategy. In January, the company founded Medios Digital GmbH, a new subsidiary that will promote the digitization of the pharmaceutical wholesale. Two months later, Medios purchased real estate in Berlin-Charlottenburg to centralize all activities of the group at the new location starting 2018 and to expand the manufacturing capacity for personalized drugs significantly. In June, the Supervisory Board expanded the Management Board, consisting of Manfred Schneider (CEO) and Matthias Gärtner (CFO), from two to three members and appointed Mi-Young Miehler, Managing Director of the subsidiaries Medios Pharma GmbH and Medios Digital GmbH, as Chief Operating Officer (COO).
At the beginning of the second half-year 2017, Medios reported further successes. Firstly, the successful strategic partnership with the pharmaceutical wholesaler Cranach Pharma was solidified. Subsequently, Medios secured further growth capital by successfully placing new shares with institutional investors. Afterwards, the company acquired additional cleanroom capacities and thus can start the already announced expansion of its manufacturing capacities for personalized medicine ahead of schedule.
Matthias Gärtner, CFO of Medios AG: “We aim for solid growth in sales with simultaneously increased profits. This is also reflected in our strategic decisions. At the Annual General Meeting, our shareholders have demonstrated impressively that they are standing behind us.”
The Annual General Meeting of Medios AG took place on August 28, 2017 in Berlin. There, all proposed resolutions on the agenda were adopted. The average approval rate was around 99 percent. In total, around 72 percent of the share capital was represented during voting.
For more information on the Medios AG’s performance in the first half-year of 2017, please see the half-year financial report, which is available for download at https://medios.ag/en/investor-relations/financial-reports/.
Medios is one of the leading competence partners and solutions providers for specialty pharmaceuticals in Germany. These are medicines for patients with rare or chronic diseases such as cancer, HIV and hepatitis, whose personalized therapy is often tedious and cost-intensive due to their individual requirements.
With our subsidiaries Medios Pharma, Medios Manufaktur and Medios Digital we connect individual market players to form cooperating partners. Our goal is to provide partners and customers with integrated solutions along the value chain, ensuring optimal patient care.
Medios AG is Germany’s first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.
Kirchhoff Consult AG
Telephone: +49 40 60918618
Fax: +49 40 60918660
Email: firstname.lastname@example.org www.kirchhoff.de
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward- looking statements contained in this notification.
* Historical basic figures (IFRS) in: Pro-Forma Consolidated Financial Statement IFRS 2015-16, Medios AG, 30.06.2016, https://medios.ag/en/wp-content/uploads/sites/3/2016/06/pro-forma-konzernabschluesse_ifrs_2015-16.pdf